Clinical trial
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
NCT00112736 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00112736 |
|---|---|
| Title | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma |
| Official title | Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma and 1 more |
| Intervention type | Drug, Other, Procedure |
| Interventions | erlotinib, temsirolimus, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study |
| Enrollment | 69 |
| Start date | Apr 1, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2014 |
| First posted | Jun 3, 2005 |
| Last update posted | Jun 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: